Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-008: Pembrolizumab + lenvatinib vs docetaxel in previously treated metastatic NSCLC
jRCT2080224918Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + lenvatinib, Docetaxel and Lenvatinib monotherapy (3 arms). Primary endpoints: Overall survival (OS) and Progression-free survival (PFS). Started Oct 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224918.